Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID‐19 in type 2 diabetes

Submitted by Anonymous (not verified) on

paper: Alzaid, F., Julla, J., Diedisheim, M., Potier, C., Potier, L., Velho, G., Gaborit, B., Manivet, P., Germain, S., Vidal‐Trecan, T., Roussel, R., Riveline, J., Dalmas, E., Venteclef, N. and Gautier, J. (2020). Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID‐19 in type 2 diabetes. EMBO Mol Med https://doi.org/10.15252/emmm.202013038
contributor: Fawaz Alzaid and Jean-François Gautier
contributor_organization: Sorbonne Université, Université de Paris, INSERM, AP-HP
contributor_email: fawaz.alzaid@gmail.com; jean-francois.gautier@aphp.fr

 

    • description: Immune cell population frequencies in peripheral blood of hospitalised patients with COVID-19 that have type-2 diabetes or are non-diabetic. Patients were further separated into those requiring critical care and those not requiring critical care.
    • exact_source: https://doi.org/10.15252/emmm.202013038
    • tissue: PBMC
    • immune_exposure: COVID-19 infection +/- type-2 diabetes +/- critical care
    • cohort: adults: 52 y to 77 y
    • comparison: diabetic versus non-diabetes
    • repository_id: NA
    • platform: NA
    • response_components: lymphocytes, monocytes
    • response_behavior: down, down
        • description: Immune cell population frequencies in peripheral blood of hospitalised patients with COVID-19 that have type-2 diabetes or are non-diabetic. Patients were further separated into those requiring critical care and those not requiring critical care.
        • exact_source: https://doi.org/10.15252/emmm.202013038
        • tissue: PBMC
        • immune_exposure: COVID-19 infection +/- type-2 diabetes +/- critical care
        • cohort: adults: 52 y to 77 y
        • comparison: Critical care versus non-critical care
        • repository_id: NA
        • platform: NA
        • response_components: lymphocytes, monocytes
        • response_behavior: down, down

 

PMID
32816392
authors
Alzaid, Fawaz et al
abstract
Early in the COVID‐19 pandemic, type 2 diabetes (T2D) was marked as a risk‐factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at‐risk groups based on immuno‐inflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated with COVID‐19 severity in T2D. Broad‐spectrum immunophenotyping quantified 15 leukocyte populations in peripheral circulation from a cohort of 45 hospitalised COVID‐19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxic CD8(+) lymphocytes was associated with severe COVID‐19 and requirement for intensive care in both non‐diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classical CD14(Hi) CD16(‐) monocytes were specifically associated with severe COVID‐19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type‐1 interferon pathway (IL6, IL8, CCL2, INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity of COVID‐19 in T2D. These findings allow precise identification of T2D patients with severe COVID‐19 as well as provide evidence that the type‐1 interferon pathway may be an actionable therapeutic target for future studies.
status
review complete
curator
reviewer
journal
EMBO Mol Med
date review completed
year of publication
2020
In Dashboard
Yes